-
Ultimovacs ASA announces revised terms of the employee share option program
-
Ultimovacs ASA announces revised terms of the employee share option program
-
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
-
Ultimovacs provides update from Phase I study in malignant melanoma: Continued strong overall survival in patients treated with UV1 cancer vaccine and pembrolizumab
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
-
Ultimovacs ASA Reports First Quarter 2024 Financial Results and Provides General Business Update
-
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
-
Ultimovacs ASA: Invitation to first quarter 2024 results webcast presentation
